TREMFYA® (guselkumab) Maintains Key Efficacy Endpoints Through Three Years for Adults with Moderately to Severely Active Crohn's Disease in a Phase 2 Study kptv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kptv.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new efficacy and safety data from the Phase 3 QUASAR Induction Study.
that cause chronic inflammation of the gastrointestinal tract.6 Prolonged inflammation results in damage to the GI tract.6 The exact cause of IBD is unknown but may be the result of the immune. | May 9, 2023